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Despite advances in critical care medicine, neonatal sepsis remains a major cause 
of morbidity and mortality worldwide, with the greatest risk affecting very low birth 
weight, preterm neonates. The presentation of neonatal sepsis varies markedly from 
its presentation in adults, and there is no clear consensus definition of neonatal sepsis. 
Previous work has demonstrated that when neonates become septic, death can occur 
rapidly over a matter of hours or days and is generally associated with inflammation, 
organ injury, and respiratory failure. Studies of the transcriptomic response by neonates 
to infection and sepsis have led to unique insights into the early proinflammatory and 
host protective responses to sepsis. Paradoxically, this early inflammatory response in 
neonates, although lethal, is clearly less robust relative to children and adults. Similarly, 
the expression of genes involved in host protective immunity, particularly neutrophil 
function, is also markedly deficient. As a result, neonates have both a diminished 
inflammatory and protective immune response to infection which may explain their 
increased risk to infection, and their reduced ability to clear infections. Such studies 
imply that novel approaches unique to the neonate will be required for the development 
of both diagnostics and therapeutics in this high at-risk population.
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inTRODUCTiOn
Neonatal sepsis is a major health-care burden worldwide, accounting for approximately 1.4 million 
neonatal deaths annually (1). Preterm infants are particularly susceptible to sepsis and have a 
higher risk of long-term complications and mortality than term infants (2). Despite advances in 
the delivery of neonatal intensive care, improving outcomes as well as diagnostic and prognostic 
accuracy in neonatal sepsis have been challenging (3).
The diagnosis of neonatal sepsis relies on the subjective interpretation of each case. This stems 
from a lack of specificity for clinical signs and symptoms (4) and suboptimal predictive ability of 
routine laboratory tests (5). Even blood cultures, the “gold-standard”, result positive in fewer than 
10% of cases of suspected sepsis (6, 7). The subjectivity of the clinicians approach to neonatal 
sepsis is further demonstrated by the observation that intraregional variation of antibiotic usage 
in the neonatal intensive care unit can range up to 40-fold (8). Underlying the diagnostic and 
prognostic challenges for this population is the absence of a consensus definition of neonatal 
sepsis to align research efforts (2).
FiGURe 1 | Distinct features of the neonatal immunity.
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The classification of neonatal sepsis is dependent on timing of 
onset; early-onset neonatal sepsis (EOS) occurs in the first 72 h 
of life, while late-onset neonatal sepsis (LOS) occurs after the 
first 72 h and is considered to have been contracted postnatally 
(9). The primary etiologies of EOS remain group B streptococcal 
(GBS) infection, despite a reduction in vertical transmission by 
intrapartum antibiotic prophylaxis, and Escherichia coli, which 
is increasing in very low birth weight (VLBW, <1,500  g birth 
weight) preterm neonates (3). In contrast, LOS is most commonly 
caused by coagulase-negative staphylococci and occurs primarily 
in VLBW neonates (3). The risk factors for EOS are more closely 
related to vertical maternal transmission (GBS colonization, pre-
mature rupture of membranes, maternal urinary tract infection, 
etc.), while LOS tends to be associated with the shortcomings of 
long-term critical care hospitalization (invasive procedures, intu-
bation, prolonged indwelling catheters, interruption of natural 
barriers, etc.), as may be expected in very preterm and extremely 
preterm neonates (1).
The neonatal adaptive immune system lacks the capacity to 
support a robust response to infection (10) (Figure 1). The adap-
tive immune response in neonates differs dramatically from that 
of children and adults. Neonatal T cells have been categorized 
as being both anti-inflammatory and toleragenic, a functional 
phenotype that appears to be programed into the hematopoietic 
stem cell (HSC) development of neonates (11). Mold and col-
leagues have shown that different populations of HSCs are active 
at various stages of development, and neonates possess HSCs 
whose T cell lineage is biased toward tolerance (12). This premise 
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is also consistent with the findings of Elahi who demonstrated 
that immature erythroid populations (CD71+) found in neonates 
are immunosuppressive and concluded that these cells increase 
the risk of infection (13). However, Wynn et  al. demonstrated 
that CD71+ erythroid cell depletion, adoptive transfer of CD71+ 
cells, or both (depletion followed by adoptive transfer) had no 
impact on murine neonatal polymicrobial sepsis survival, and 
CD71+ cells in human neonates were revealed to be enucleated 
reticulocytes (14).
Because an adaptive immune response favors tolerance and 
contributes little to host protective immunity, the neonate pre-
dominantly relies on an immature innate immunity (15). These 
deficiencies are linked to the developmental age of the neonate 
and place the preterm infant at the greatest risk of developing sep-
sis (16). Despite a significant dependence upon innate immunity, 
neonates have an underdeveloped innate response to infection 
including decreased cytokine production and reduced neutrophil 
and dendritic cell function as compared to adults, which further 




Since 1990 and the original sequencing of the human genome, 
the growth of genomic research has greatly expanded our 
understanding of the underlying response to infection in 
neonates. In the past decade alone, genome-wide association 
studies and transcriptomic analyses have become routine and 
are currently being used for precision medicine initiatives. 
Genome-wide transcriptomics in particular have become 
routine discovery tools to better understand tumor and host 
tissue responses, either by microarray or ribonucleic acid (RNA) 
sequencing.
With these new tools have come new challenges (19). 
Bioinformatics have had difficulty keeping up with both the 
statistical approaches used, as well as the extraction of useable 
information from these vast amounts of data. Development of 
biomarkers based on these technologies has been especially chal-
lenging due to the initial inability to replicate the findings in con-
firmatory studies (20). There have been some novel approaches to 
overcoming the hurdles associated with high-throughput studies 
conducted in small data sets (21) and the difficulty in replicating 
the findings. Sweeney et al. have taken a meta-analysis approach 
using publically available datasets of septic adults and children to 
extract robust transcriptomic changes that are seen across a large 
number of individual smaller studies (22, 23).
Investigations into the transcriptomic responses to infection 
have led to identification of genomic alterations associated with 
both infection and developmental age (24, 25) and provided 
new approaches to diagnostics, prognostics, and therapeutics 
in sepsis (26). In this narrative review, we focus on the current 
understanding of the neonatal transcriptomic response to sepsis 
and how this knowledge may be used to improve our investiga-
tive and clinical approach to neonatal sepsis.
Among pediatric patients with septic shock, neonates dem-
onstrate significant reduction in the change of gene expression 
representing key inflammation and immunity signaling pathways 
compared to infants, toddlers, and children (25). As expected, 
septic neonates have a significant upregulation, albeit attenu-
ated, of several genes involved in innate immunity compared to 
uninfected neonates (24, 27, 28). The neonatal innate immune 
response to sepsis is driven by an increased expression of neutro-
phils and monocytes (28). By contrast, there is a net suppression 
of the adaptive immune response as characterized by a decrease 
in expression levels by T and B cells (28). Genome-wide expres-
sion profiles of neonates differ significantly between early- and 
late-onset sepsis (27), suggesting that the host immune response 
is determined in part by the postnatal age at the onset of sep-
sis. Interestingly, genome-wide expression profiles of VLBW 
neonates with sepsis also differ between Gram-positive and 
Gram-negative sepsis, suggesting that the neonatal response to 
sepsis varies depending on the inducing pathogen (24). Similar 
responses have been seen in adults when exposed ex vivo to 
Gram-negative and Gram-positive pathogens (29).
Studies on the genomic response of whole blood or enriched 
blood leukocytes from neonates confirm this attenuation of early 
inflammatory responses. Compared to infants and children, 
neonates with septic shock downregulate expression of key 
nuclear factor kappa B pathway-related genes (25). Neonatal 
mice likewise have an attenuated early inflammatory response 
to infection compared to adults, including a diminished 
upregulation of tumor necrosis factor alpha (TNFα)-related 
genes (30). This raises an interesting paradox. If neonates have 
a weakened early inflammatory response compared to adults, 
but early mortality is more common, there can only be a limited 
number of explanations. The first is that neonates are markedly 
more sensitive to the inflammatory signals produced early in 
response to microbial infection. Despite a diminished inflam-
matory response, that response is much more likely to result in 
endothelial injury, circulatory failure, organ injury, and death. 
An alternative explanation is that the attenuation in host inflam-
matory responses parallels an attenuation of host protective 
mechanisms. In this case, an early failure to control bacterial 
growth leads to rapid colonization of organs, cardiovascular 
failure, and death. Support for this latter hypothesis comes from 
genomic and functional studies on innate and adaptive immu-
nity in neonates (25, 31). It is likely, however, that both processes 
are active.
The transcriptomic differences seen in human neonates 
are in agreement with transcriptional changes seen in murine 
models of polymicrobial sepsis in which neonatal mice exhibit 
increased mortality compared to young adult mice. These 
models demonstrate that neonates do not depend on an intact 
adaptive immune system to provide host protective immunity 
(15). In  response to early sepsis, neonates also have decreased 
ability to recruit innate immune effector cells to the source 
of infection, with recruited cells having decreased ability to 
produce reactive oxygen species compared to adult mice (30). 
This is best revealed in Figure 2 which examined whole blood 
leukocyte gene expression from young adult and neonatal mice. 
Young adult mice had the characteristic increase in the gene 
expression of proteins involved predominantly in inflammation 
and innate immunity. Not only were these increases absent in 
FiGURe 2 | Pathway analysis of gene expression from blood leukocytes of neonates and young adults subjected to sepsis. Modified from Gentile et al. 
(30). Copyright 2014. The American Association of Immunologists, Inc. Heat maps show the gene expression of the functional category hematological systems 
development and function. Blue represents pathways with an overexpression of genes leading to downregulation of the pathway, whereas orange represents 
pathways with an overexpression of genes whose activation will lead to upregulation of the pathway. The corresponding tables show the top 10 pathways and their 
corresponding z-score within the functional category. Blue indicates the pathway is significantly downregulated, and red indicates the pathway is significantly 
upregulated.
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neonatal mice, but there was also a downregulation of genes 
involved in the development of an adaptive immune response.
Likewise, significant reductions in proinflammatory plasma 
cytokine concentrations exist among neonatal mice as compared 
to adult mice including interleukin (IL)-1α, IL-1β, IL-12p40, 
IL-13, TNFα, granulocyte-macrophage colony-stimulating 
factor (GM-CSF), macrophage inflammatory protein-1 beta, 
regulated on activation normal T-cell expressed and secreted, 
and interferon gamma (32). Analysis 24 h after sepsis reveals 
neonatal plasma cytokine concentrations are equivalent to 
young adults except for IL-1β and IL-12p40 which remain 
diminished. Based on functional pathway analysis, isolated 
leukocytes from neonatal mice have significant downregulation 
of pathways 24 h after sepsis corresponding to the development 
of leukocytes, quantity of T lymphocytes, and proliferation of 
immune cells (30). In addition to transcriptomic differences in 
the response to infection, the baseline transcriptome differed 
significantly between neonatal and adult mice leukocytes by 
5,798 probe sets.  (30). The representative genes demonstrate 
functional suppression of the adaptive immunity and down-
regulation of genes in pathways involved with the activation of 
the innate immunity.
When evaluating these studies of sepsis in mice, it is important 
to note key differences between murine and human immunity. 
Whereas the predominating circulating leukocyte in humans is 
the neutrophil (50–70%), the lymphocyte is the predominating 
circulating leukocyte in mice (75–90%) (33). Also, neutrophils 
are an abundant source of defensins in humans, while mice lack 
these antimicrobial peptides (34). In addition to differences in 
innate immunity, humans and mice also exhibit differences 
in adaptive immunity. These differences include, but are not 
limited to, expression of Fc receptors, immunoglobulin isotypes 
and antibody class switching, and T cell receptor signaling and 
costimulation (35).
Many of these changes in gene expression are recapitulated 
phenotypically. Neonates exhibit defective neutrophil func-
tion compared to adults including adherence, chemotaxis, 
phagocytosis, neutrophil respiratory burst activity (NRBA), 
and release of neutrophil extracellular traps (NETs) (36–40). 
Merry and colleagues demonstrated that neutrophils from 
healthy neonates have impaired chemotaxis compared to 
healthy adults and even greater impairment was observed 
among septic neonates (39). At birth, neutrophil phagocytosis 
is significantly reduced in both preterm and term neonates 
as compared to adults; however, this impairment appears to 
resolve by 3  days after birth (38). This may further explain 
some of the observed differences in host response to early- and 
late-onset sepsis, although an additional explanation may be 
the use of umbilical cord blood (UCB) compared to peripheral 
blood in this study. UCB may be impacted by administration 
of antepartum antibiotics as well as the physiological stresses 
of labor. Healthy preterm neonates have fewer circulating 
neutrophils compared to term neonates (41) and exhibit a 
lower percentage of NRBA compared to term neonates and 
TABLe 1 | Summary of strategies aimed at improving the neonatal immune response.
Strategy Proposed mechanism Reference
Granulocyte transfusions Addition of functional granulocytes (44)
GM-CSF, G-CSF Stimulates proliferation, differentiation, and functional activity of myeloid precursors (45, 46)
Intravenous immunoglobulin Increase antibody titer and potential antigen–antibody interactions (47–50)
Activated protein C Anti-inflammatory and anti-coagulant properties (51, 52)
Glutamine Enhance function of immune cells (53, 54)
Pentoxifylline Inhibit release of TNFα (55)
Anti-endotoxin antibodies Inhibit deleterious effects of endotoxins (56)
Probiotics Maintain integrity of the intestinal barrier function (57)
Breast milk Provides immunoglobulin A, lactoferrin, oligosaccharides (58)
Anti-IL17A, anti-IL17A receptor antibodies Inhibit pathological proinflammatory effects of IL-18 (59)
Toll-like receptor agonists Augment innate immunity (15)
Topical emollient Protect against skin breakdown, prevent pathogens entry (60)
Lactoferrin Iron sequestration, disruption of microbial cell membranes (61)
FFP Provides humoral immune factors (62)
GM-CSF, granulocyte-macrophage colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor; FFP, fresh frozen plasma; IL, interleukin; TNFα, tumor necrosis factor alpha.
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adults (37). In samples from septic patients, both term and 
preterm neonates demonstrate diminished NRBA. Neonatal 
neutrophils additionally fail to form NETs following an hour 
of ex vivo lipopolysaccharide (LPS) stimulation, whereas adult 
neutrophils readily form NETs which bind and kill bacteria 
extracellularly (40). However, neonatal neutrophils began to 
form NETs following 2 h of LPS stimulation and nearly reach 
adult levels by 3 h of stimulation (42).
FUTURe DiReCTiOnS
Successful modulation of the neonatal immune system to reduce 
the frequency of sepsis, sepsis mortality, and sepsis survivor mor-
bidity would represent substantial advances in the field. Despite 
multiple attempts to modulate neonatal immunity in an effort to 
improve sepsis outcomes in neonates, most therapies have been 
largely unsuccessful to date (43). This is not particularly surpris-
ing given the equivalent failures of immune modulation in adult 
sepsis, which have prompted clinical trials with rapid molecular 
assessments of immune status and provision of the appropriate 
immunomodulatory strategy (anti-inflammatory or immune 
stimulation) (https://clinicaltrials.gov/ct2/show/NCT02576457). 
Previous immunomodulatory strategies which have been studied 
in neonates include granulocyte transfusions, administration of 
GM-CSF, intravenous immunoglobulin, activated protein C, 
glutamine, pentoxifylline, anti-endotoxin antibodies, probiotics, 
and breast milk (43) (Table 1). With the exceptions of breast milk 
and bovine lactoferrin, these therapies have shown minimal to no 
reduction in sepsis incidence, and no intervention is associated 
with an improvement in sepsis-related mortality (43).
Therapeutics aimed at preventing or treating neonatal sepsis 
must take into consideration the unique immunological status of 
the subject. One example of this is the observation that healthy pre-
term neonates have elevated blood concentrations of IL-18 (63), a 
proinflammatory member of the IL-1 superfamily. Healthy adults 
do not manifest high concentrations of circulating IL-18 (64), and 
their increase in sepsis is markedly lower than the increases seen 
in neonates (65). Targeting the IL-18/IL-17A axis through the 
use of neutralizing IL-17 receptor antibodies represents a novel 
approach to treating neonatal sepsis (59). While IL-18 is known 
to exert proinflammatory effects such as increased neutrophil 
phagocytosis and production of reactive oxygen species, paradoxi-
cally, IL-18-null (IL-18−/−) neonatal mice demonstrated markedly 
improved survival and reduced bacteremia in comparison to 
wild-type neonatal mice when challenged with polymicrobial 
sepsis (59). Unlike human preterm neonates, healthy neonatal 
mice do not exhibit increased circulating IL-18. When IL-18 was 
given to septic mice to mimic the human condition, mortality 
was dramatically increased compared to septic mice alone and 
was associated with increased bacteremia, intestinal injury, and 
an increased systemic inflammatory response predominated by 
IL-17A. The deleterious effects of IL-18 on neonatal sepsis survival 
were dependent upon IL-1R1 signaling and IL-17A production 
by gamma delta cells in the intestine and lung (59). Compared to 
wild-type or isotype control treated mice, transgenic mice lack-
ing IL-17A or wild-type mice that received antibody-mediated 
receptor blockade of IL-17A through IL-17A receptor or cytokine 
neutralizing antibodies exhibited markedly reduced mortality to 
sepsis (59). Currently, two antibodies directed against IL-17A 
(secukinumab and ixekizumab) have obtained FDA approval for 
use in other inflammatory diseases, and an additional antibody 
against IL-17A receptor (brodalumab) is currently awaiting final 
FDA approval. These therapies may prove beneficial in septic 
neonates.
The prevention rather than treatment of sepsis is an alter-
native approach and would be expected to have a significant 
benefit over the current reactive paradigm. Defined exposure 
to non-infectious components of bacteria that are recognized 
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by the innate immune system is one approach being considered 
as a means to positively modify neonatal immune responses. 
Of the adjuvant therapies currently being studied, toll-like 
receptor (TLR) agonists appear most promising (66). TLRs 
play a vital role in early recognition of microbial invasion and 
activation of the innate immunity (67). TLRs are membrane-
spanning receptors present on the cell surface and within 
intracellular vesicles of leukocytes and other non-immune 
cell populations such as endothelial cells and fibroblasts (68). 
Stimulation of these receptors occurs through the binding of 
ligands, specifically, pathogen-associated molecular patterns 
(PAMPs) (69). PAMPs may include components of either 
the bacterial or fungal cell wall or membrane such as LPS, 
peptidoglycan, or flagellin, or intracellular components such 
as single- or double-stranded RNA or deoxyribonucleic acid. 
Activation of these receptors induces downstream molecular 
signaling events which ultimately triggers the production of 
inflammatory cytokines, type I interferons, chemokines, and 
antimicrobial peptides (70).
Toll-like receptor agonists, in particular those affecting 
TLR 4 and TLR 7/8, have been shown to augment innate 
immunity, magnify but abbreviate the early systemic inflam-
matory response, reduce bacteremia, and increase survival to 
polymicrobial sepsis in neonatal murine models (15). Burl and 
colleagues also demonstrated that in vitro stimulation of new-
born cord blood with TLR agonists led to significant produc-
tion of TNFα, IL-6, IL-1β, and IL-10 (71). Interestingly, several 
first-generation inactivated and attenuated vaccines including 
rabies, typhoid, and Bacillus Calmette–Guérin (BCG) possess 
inherent TLR activity (72). Hence, the inclusion of adjuvants in 
vaccines has provided non-specific heterologous benefits and 
enhanced immune responses in traditionally poor-responding 
populations such as neonates. When BCG was administered 
at birth to newborns in sub-Saharan Africa, there was a 41% 
reduction in all-cause mortality at 12  months among VLBW 
neonates, which was attributed to fewer cases of neonatal sepsis, 
respiratory infections, and fever (73).
COnCLUSiOn
Neonatal sepsis is prominent cause of morbidity and mortality. A 
clear understanding of the neonatal response to sepsis represents 
a critical knowledge gap that greatly limits the opportunity to 
discover novel diagnostics and therapies to treat and potentially 
prevent this devastating disease. Evaluation of the transcriptomic 
response of blood leukocyte populations offers both a global view 
of the neonatal response to infection and sepsis, and the potential 
for identification of novel therapeutic opportunities, diagnostic 
tests, and prognostic markers. Accurate biomarkers would 
facilitate both targeted treatment, thus avoiding the overuse of 
empiric antibiotics in non-septic neonates, and an enrichment 
strategy that facilitates better selection of study participants for 
future clinical trials.
AUTHOR COnTRiBUTiOnS
All the authors contributed extensively to the work presented 
in this paper. SR, JS, and JM wrote the manuscript. SL, JW, and 
LM gave conceptual advice and edited the manuscript.
FUnDinG
This work was supported by K08 GM106143, R01 GM097531, 
and P50 GM111152 awarded by the National Institute of General 
Medical Sciences (NIGMS). JS and JM were supported by a 
NIGMS post-doctoral training grant in burns and trauma (T32 
GM008721).
ReFeRenCeS
1. Shane AL, Stoll BJ. Neonatal sepsis: progress towards improved outcomes. 
J Infect (2014) 68(Suppl 1):S24–32. doi:10.1016/j.jinf.2013.09.011 
2. Wynn JL. Defining neonatal sepsis. Curr Opin Pediatr (2016) 28:135–40. 
doi:10.1097/MOP.0000000000000315 
3. Camacho-Gonzalez A, Spearman PW, Stoll BJ. Neonatal infectious diseases: 
evaluation of neonatal sepsis. Pediatr Clin North Am (2013) 60:367–89. 
doi:10.1016/j.pcl.2012.12.003 
4. Gerdes JS. Diagnosis and management of bacterial infections in the 
neonate. Pediatr Clin North Am (2004) 51:939–59, viii–ix. doi:10.1016/j.
pcl.2004.03.009 
5. Benitz WE. Adjunct laboratory tests in the diagnosis of early-onset neonatal 
sepsis. Clin Perinatol (2010) 37:421–38. doi:10.1016/j.clp.2009.12.001 
6. Cantey JB, Wozniak PS, Sanchez PJ. Prospective surveillance of antibiotic 
use in the neonatal intensive care unit: results from the SCOUT study. 
Pediatr Infect Dis J (2015) 34:267–72. doi:10.1097/INF.0000000000000542 
7. Hornik CP, Fort P, Clark RH, Watt K, Benjamin DK Jr, Smith PB, et al. Early 
and late onset sepsis in very-low-birth-weight infants from a large group of 
neonatal intensive care units. Early Hum Dev (2012) 88(Suppl 2):S69–74. 
doi:10.1016/S0378-3782(12)70019-1 
8. Schulman J, Dimand RJ, Lee HC, Duenas GV, Bennett MV, Gould JB. 
Neonatal intensive care unit antibiotic use. Pediatrics (2015) 135:826–33. 
doi:10.1542/peds.2014-3409 
9. Shane AL, Stoll BJ. Recent developments and current issues in the epidemi-
ology, diagnosis, and management of bacterial and fungal neonatal sepsis. 
Am J Perinatol (2013) 30:131–41. doi:10.1055/s-0032-1333413 
10. Zaghouani H, Hoeman CM, Adkins B. Neonatal immunity: faulty T-helpers 
and the shortcomings of dendritic cells. Trends Immunol (2009) 30:585–91. 
doi:10.1016/j.it.2009.09.002 
11. Gibbons D, Fleming P, Virasami A, Michel ML, Sebire NJ, Costeloe K, et al. 
Interleukin-8 (CXCL8) production is a signatory T cell effector function 
of human newborn infants. Nat Med (2014) 20:1206–10. doi:10.1038/ 
nm.3670 
12. Mold JE, Venkatasubrahmanyam S, Burt TD, Michaelsson J, Rivera JM, 
Galkina SA, et  al. Fetal and adult hematopoietic stem cells give rise to 
distinct T cell lineages in humans. Science (2010) 330:1695–9. doi:10.1126/
science.1196509 
13. Elahi S, Ertelt JM, Kinder JM, Jiang TT, Zhang X, Xin L, et  al. Immu-
nosuppressive CD71+ erythroid cells compromise neonatal host defence 
against infection. Nature (2013) 504:158–62. doi:10.1038/nature12675 
14. Wynn JL, Scumpia PO, Stocks BT, Romano-Keeler J, Alrifai MW, Liu JH, 
et al. Neonatal CD71+ erythroid cells do not modify murine sepsis mortality. 
J Immunol (2015) 195:1064–70. doi:10.4049/jimmunol.1500771 
15. Wynn JL, Scumpia PO, Winfield RD, Delano MJ, Kelly-Scumpia K, Barker 
T, et  al. Defective innate immunity predisposes murine neonates to poor 
sepsis outcome but is reversed by TLR agonists. Blood (2008) 112:1750–8. 
doi:10.1182/blood-2008-01-130500 
7Raymond et al. Neonatal Response to Sepsis
Frontiers in Pediatrics | www.frontiersin.org February 2017 | Volume 5 | Article 14
16. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. 
IgG placental transfer in healthy and pathological pregnancies. Clin Dev 
Immunol (2012) 2012:985646. doi:10.1155/2012/985646 
17. Kollmann TR, Crabtree J, Rein-Weston A, Blimkie D, Thommai F, Wang 
XY, et  al. Neonatal innate TLR-mediated responses are distinct from 
those of adults. J Immunol (2009) 183:7150–60. doi:10.4049/jimmunol. 
0901481 
18. Levy O. Innate immunity of the newborn: basic mechanisms and clinical 
correlates. Nat Rev Immunol (2007) 7:379–90. doi:10.1038/nri2075 
19. Mira JC, Moldawer LL. Sepsis diagnostics: from discovery to applica-
tion. Crit Care Med (2017) 45:129–30. doi:10.1097/CCM.00000000000 
02117 
20. Dopazo J. Genomics and transcriptomics in drug discovery. Drug Discov 
Today (2014) 19:126–32. doi:10.1016/j.drudis.2013.06.003 
21. Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A. Targeted therapies: 
how personal should we go? Nat Rev Clin Oncol (2011) 9:87–97. doi:10.1038/
nrclinonc.2011.164 
22. Sweeney TE, Khatri P. Benchmarking sepsis gene expression diag-
nostics using public data. Crit Care Med (2017) 45:1–10. doi:10.1097/
CCM.0000000000002021 
23. Sweeney TE, Shidham A, Wong HR, Khatri P. A comprehensive time-
course-based multicohort analysis of sepsis and sterile inflammation reveals 
a robust diagnostic gene set. Sci Transl Med (2015) 7:287ra71. doi:10.1126/
scitranslmed.aaa5993 
24. Cernada M, Serna E, Bauerl C, Collado MC, Perez-Martinez G, Vento 
M. Genome-wide expression profiles in very low birth weight infants 
with neonatal sepsis. Pediatrics (2014) 133:e1203–11. doi:10.1542/peds. 
2013-2552 
25. Wynn JL, Cvijanovich NZ, Allen GL, Thomas NJ, Freishtat RJ, Anas N, et al. 
The influence of developmental age on the early transcriptomic response 
of children with septic shock. Mol Med (2011) 17:1146–56. doi:10.2119/
molmed.2011.00169 
26. Srinivasan L, Kirpalani H, Cotten CM. Elucidating the role of genomics 
in neonatal sepsis. Semin Perinatol (2015) 39:611–6. doi:10.1053/j.
semperi.2015.09.008 
27. Wynn JL, Guthrie SO, Wong HR, Lahni P, Ungaro R, Lopez MC, et  al. 
Postnatal age is a critical determinant of the neonatal host response to sepsis. 
Mol Med (2015) 21:496–504. doi:10.2119/molmed.2015.00064 
28. Smith CL, Dickinson P, Forster T, Craigon M, Ross A, Khondoker MR, 
et al. Identification of a human neonatal immune-metabolic network asso-
ciated with bacterial infection. Nat Commun (2014) 5:4649. doi:10.1038/
ncomms5649 
29. Feezor RJ, Oberholzer C, Baker HV, Novick D, Rubinstein M, Moldawer 
LL, et al. Molecular characterization of the acute inflammatory response to 
infections with Gram-negative versus Gram-positive bacteria. Infect Immun 
(2003) 71:5803–13. doi:10.1128/IAI.71.10.5803-5813.2003 
30. Gentile LF, Nacionales DC, Lopez MC, Vanzant E, Cuenca A, Cuenca 
AG, et  al. Protective immunity and defects in the neonatal and elderly 
immune response to sepsis. J Immunol (2014) 192:3156–65. doi:10.4049/
jimmunol.1301726 
31. Mathias B, Mira JC, Rehfuss JP, Rincon JC, Ungaro R, Nacionales DC, et al. 
LPS stimulation of cord blood reveals a newborn-specific neutrophil tran-
scriptomic response and cytokine production. Shock (2016). doi:10.1097/
SHK.0000000000000800 
32. Wynn JL, Scumpia PO, Delano MJ, O’Malley KA, Ungaro R, Abouhamze 
A, et  al. Increased mortality and altered immunity in neonatal sepsis 
produced by generalized peritonitis. Shock (2007) 28:675–83. doi:10.1097/
SHK.0b013e3180556d09
33. Doeing DC, Borowicz JL, Crockett ET. Gender dimorphism in differen-
tial peripheral blood leukocyte counts in mice using cardiac, tail, foot, 
and saphenous vein puncture methods. BMC Clin Pathol (2003) 3:3. 
doi:10.1186/1472-6890-3-3 
34. Eisenhauer PB, Lehrer RI. Mouse neutrophils lack defensins. Infect Immun 
(1992) 60:3446–7. 
35. Mestas J, Hughes CC. Of mice and not men: differences between mouse 
and human immunology. J Immunol (2004) 172:2731–8. doi:10.4049/
jimmunol.172.5.2731 
36. Anderson DC, Hughes BJ, Smith CW. Abnormal mobility of neonatal 
polymorphonuclear leukocytes. Relationship to impaired redistribution 
of surface adhesion sites by chemotactic factor or colchicine. J Clin Invest 
(1981) 68:863–74. doi:10.1172/JCI110341 
37. Drossou V, Kanakoudi F, Tzimouli V, Sarafidis K, Taparkou A, Bougiouklis 
D, et al. Impact of prematurity, stress and sepsis on the neutrophil respira-
tory burst activity of neonates. Biol Neonate (1997) 72:201–9. doi:10.1159/ 
000244485 
38. Filias A, Theodorou GL, Mouzopoulou S, Varvarigou AA, Mantagos S, 
Karakantza M. Phagocytic ability of neutrophils and monocytes in neonates. 
BMC Pediatr (2011) 11:29. doi:10.1186/1471-2431-11-29 
39. Merry C, Puri P, Reen DJ. Defective neutrophil actin polymerisation 
and chemotaxis in stressed newborns. J Pediatr Surg (1996) 31:481–5. 
doi:10.1016/S0022-3468(96)90479-0 
40. Yost CC, Cody MJ, Harris ES, Thornton NL, McInturff AM, Martinez 
ML, et al. Impaired neutrophil extracellular trap (NET) formation: a novel 
innate immune deficiency of human neonates. Blood (2009) 113:6419–27. 
doi:10.1182/blood-2008-07-171629 
41. Prosser A, Hibbert J, Strunk T, Kok CH, Simmer K, Richmond P, et  al. 
Phagocytosis of neonatal pathogens by peripheral blood neutrophils and 
monocytes from newborn preterm and term infants. Pediatr Res (2013) 
74:503–10. doi:10.1038/pr.2013.145 
42. Marcos V, Nussbaum C, Vitkov L, Hector A, Wiedenbauer EM, Roos 
D, et  al. Delayed but functional neutrophil extracellular trap formation 
in neonates. Blood (2009) 114:4908–11; author reply 11–2. doi:10.1182/
blood-2009-09-242388 
43. Wynn JL, Neu J, Moldawer LL, Levy O. Potential of immunomodulatory 
agents for prevention and treatment of neonatal sepsis. J Perinatol (2009) 
29:79–88. doi:10.1038/jp.2009.48 
44. Pammi M, Brocklehurst P. Granulocyte transfusions for neonates with 
confirmed or suspected sepsis and neutropaenia. Cochrane Database Syst 
Rev (2011) (10):CD003956. doi:10.1002/14651858.CD003956.pub2
45. Carr R, Brocklehurst P, Dore CJ, Modi N. Granulocyte-macrophage colony 
stimulating factor administered as prophylaxis for reduction of sepsis in 
extremely preterm, small for gestational age neonates (the PROGRAMS 
trial): a single-blind, multicentre, randomised controlled trial. Lancet (2009) 
373:226–33. doi:10.1016/S0140-6736(09)60071-4 
46. Mathias B, Szpila BE, Moore FA, Efron PA, Moldawer LL. A review of 
GM-CSF therapy in sepsis. Medicine (2015) 94(50):e2044. doi:10.1097/
MD.0000000000002044
47. INIS Collaborative Group, Brocklehurst P, Farrell B, King A, Juszczak E, 
Darlow B, et  al. Treatment of neonatal sepsis with intravenous immune 
globulin. N Engl J Med (2011) 365:1201–11. doi:10.1056/NEJMoa1100441 
48. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven 
infection in neonates. Cochrane Database Syst Rev (2015) (3):CD001239. 
doi:10.1002/14651858.CD001239.pub5
49. Shah PS, Kaufman DA. Antistaphylococcal immunoglobulins to prevent 
staphylococcal infection in very low birth weight infants. Cochrane Database 
Syst Rev (2009) (2):CD006449. doi:10.1002/14651858.CD006449.pub2
50. Patel M, Kaufman DA. Anti-lipoteichoic acid monoclonal antibody 
(pagibaximab) studies for the prevention of staphylococcal bloodstream 
infections in preterm infants. Expert Opin Biol Ther (2015) 15:595–600. d
oi:10.1517/14712598.2015.1019857 
51. Goldstein B, Nadel S, Peters M, Barton R, Machado F, Levy H, et  al. 
ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) 
in children with severe sepsis. Pediatr Crit Care Med (2006) 7:200–11. 
doi:10.1097/01.PCC.0000217470.68764.36 
52. Kylat RI, Ohlsson A. Recombinant human activated protein C for severe 
sepsis in neonates. Cochrane Database Syst Rev (2012) (4):CD005385. 
doi:10.1002/14651858.CD005385.pub3
53. Poindexter BB, Ehrenkranz RA, Stoll BJ, Wright LL, Poole WK, Oh W, et al. 
Parenteral glutamine supplementation does not reduce the risk of mortality 
or late-onset sepsis in extremely low birth weight infants. Pediatrics (2004) 
113:1209–15. doi:10.1542/peds.113.5.1209 
54. Moe-Byrne T, Brown JV, McGuire W. Glutamine supplementation to prevent 
morbidity and mortality in preterm infants. Cochrane Database Syst Rev 
(2016) (4):CD001457. doi:10.1002/14651858.CD001457.pub6
8Raymond et al. Neonatal Response to Sepsis
Frontiers in Pediatrics | www.frontiersin.org February 2017 | Volume 5 | Article 14
55. Akdag A, Dilmen U, Haque K, Dilli D, Erdeve O, Goekmen T. Role of pent-
oxifylline and/or IgM-enriched intravenous immunoglobulin in the man-
agement of neonatal sepsis. Am J Perinatol (2014) 31:905–12. doi:10.1055/ 
s-0033-1363771 
56. Adhikari M, Coovadia HM, Gaffin SL, Brock-Utne JG, Marivate M, Pudifin 
DJ. Septicaemic low birthweight neonates treated with human antibodies 
to endotoxin. Arch Dis Child (1985) 60:382–4. doi:10.1136/adc.60.4.382 
57. Hartel C, Pagel J, Rupp J, Bendiks M, Guthmann F, Rieger-Fackeldey E, 
et al. Prophylactic use of Lactobacillus acidophilus/Bifidobacterium infantis 
probiotics and outcome in very low birth weight infants. J Pediatr (2014) 
165:285–9.e1. doi:10.1016/j.jpeds.2014.04.029 
58. Patel AL, Johnson TJ, Engstrom JL, Fogg LF, Jegier BJ, Bigger HR, et  al. 
Impact of early human milk on sepsis and health-care costs in very low birth 
weight infants. J Perinatol (2013) 33:514–9. doi:10.1038/jp.2013.2 
59. Wynn JL, Wilson CS, Hawiger J, Scumpia PO, Marshall AF, Liu JH, et  al. 
Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18. Proc 
Natl Acad Sci U S A (2016) 113:E2627–35. doi:10.1073/pnas.1515793113 
60. Cleminson J, McGuire W. Topical emollient for preventing infection 
in preterm infants. Cochrane Database Syst Rev (2016) (1):CD001150. 
doi:10.1002/14651858.CD001150.pub3
61. Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, et  al. 
Bovine lactoferrin supplementation for prevention of late-onset sepsis 
in very low-birth-weight neonates: a randomized trial. JAMA (2009) 
302:1421–8. doi:10.1001/jama.2009.1403 
62. Acunas BA, Peakman M, Liossis G, Davies ET, Bakoleas B, Costalos C, et al. 
Effect of fresh frozen plasma and gammaglobulin on humoral immunity 
in neonatal sepsis. Arch Dis Child Fetal Neonatal Ed (1994) 70:F182–7. 
doi:10.1136/fn.70.3.F182 
63. Sood BG, Shankaran S, Schelonka RL, Saha S, Benjamin DK Jr, Sanchez 
PJ, et  al. Cytokine profiles of preterm neonates with fungal and bacterial 
sepsis. Pediatr Res (2012) 72:212–20. doi:10.1038/pr.2012.56 
64. Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine levels in 
the serum of healthy subjects. Mediators Inflamm (2013) 2013:434010. 
doi:10.1155/2013/434010 
65. Grobmyer SR, Lin E, Lowry SF, Rivadeneira DE, Potter S, Barie PS, et  al. 
Elevation of IL-18 in human sepsis. J Clin Immunol (2000) 20:212–5. doi:
10.1023/A:1006641630904 
66. Savva A, Roger T. Targeting toll-like receptors: promising therapeutic 
strategies for the management of sepsis-associated pathology and infectious 
diseases. Front Immunol (2013) 4:387. doi:10.3389/fimmu.2013.00387 
67. Medzhitov R. Recognition of microorganisms and activation of the immune 
response. Nature (2007) 449:819–26. doi:10.1038/nature06246 
68. Cuenca AG, Wynn JL, Moldawer LL, Levy O. Role of innate immunity in 
neonatal infection. Am J Perinatol (2013) 30:105–12. doi:10.1055/s-0032- 
1333412 
69. Raymond SL, Holden DC, Mira JC, Stortz JA, Loftus TJ, et  al. Microbial 
recognition and danger signals in sepsis and trauma. Biochimica et Biophysica 
Acta (2017) (17):30026–1. doi:10.1016/j.bbadis.2017.01.013
70. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. 
Cell (2006) 124:783–801. doi:10.1016/j.cell.2006.02.015 
71. Burl S, Townend J, Njie-Jobe J, Cox M, Adetifa UJ, Touray E, et  al. Age-
dependent maturation of toll-like receptor-mediated cytokine responses 
in Gambian infants. PLoS One (2011) 6:e18185. doi:10.1371/journal.
pone.0018185 
72. Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands 
as adjuvants within human vaccines. Immunol Rev (2011) 239:178–96. 
doi:10.1111/j.1600-065X.2010.00978.x 
73. Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, et  al. 
Randomized trial of BCG vaccination at birth to low-birth-weight children: 
beneficial nonspecific effects in the neonatal period? J Infect Dis (2011) 
204:245–52. doi:10.1093/infdis/jir240 
Conflict of Interest Statement: The authors declare that the research was 
conducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.
Copyright © 2017 Raymond, Stortz, Mira, Larson, Wynn and Moldawer. This 
is an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) or licensor are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
